Human RCT
Mensch
Le Roux CW. et al. 2024
Weight reduction over 46 weeks documented in a phase-2 obesity trial
What does NOT follow: Phase-2 data; phase-3 programme SYNCHRONIZE is ongoing. Long-term data beyond 1 year pending.
Peptide entry · Metabolic
Survodutide
BI 456906 · BI-456906
Highest evidence
Human RCT
Studies recorded
2· 2 in humans
Legal status · US
UnapprovedScientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet.
Researched for
Weight reduction in obesity (SYNCHRONIZE programme)Glycaemic control in type 2 diabetesMetabolic dysfunction-associated steatohepatitis (MASH)
Official status
US: Unapproved
No FDA approval. Phase-3 programme SYNCHRONIZE is ongoing; an approval decision is expected no earlier than 2026.
At a glance
01
Mechanism of action
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
03
What the studies show
Human RCT
Mensch
Sanyal AJ. et al. 2024
Histological MASH improvement reported in a phase-2 trial over 48 weeks
What does NOT follow: Phase 2 with biopsy endpoints; phase-3 confirmation with clinical endpoints (liver disease progression) pending.
Human RCT
Mensch
Le Roux CW. et al. 2024
Gastrointestinal adverse events (nausea, diarrhoea) were dose-dependently frequent across all phase-2 trials
What does NOT follow: Profile similar to other incretin-based substances; titration phase relevant.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 168 h. Pure pharmacokinetic model — not a dosing recommendation.
Open in PK tool →Start time: t₀ = 0.0d
Repeat interval: off (single dose)
06
Routes of administration in the literature
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
In all phase-1 and phase-2 trials administered subcutaneously once weekly.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Nausea / vomiting
Most frequent events documented in phase 2; often transient during titration.
häufig, dosisabhängig
Human RCT
Transient glucose increase
Consequence of the glucagon component; clinically not significant in the obesity studies, to be monitored carefully in diabetes settings.
in einigen Phase-2-Subgruppen beobachtet
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
11
Legal status by country
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
14
Study register
Human RCTRandomised controlled trialn = 387
Le Roux CW. et al. · 2024
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Concrete results
Mean weight reduction (highest dose arm)
−18.7%
vs Placebo (−2.0%) · 46 Wochen
Human RCTRandomised controlled trialn = 293
Sanyal AJ. et al. · 2024
A phase 2 randomized trial of survodutide in MASH and fibrosis
Concrete results
Histological MASH improvement (responder rate highest arm)
83%
vs Placebo (18%) · 48 Wochen
15
Sources & method
Reviewed by
editor-placeholder
Last reviewed
2026-05-22
Get new studies on Survodutide
Science only, no sales. Unsubscribe anytime.